Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details
Close

Novavax Inc (NVAX)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Follow Novavax's earnings

Delivery Method

Status

Add to/Remove from a Portfolio Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
176.56 +34.69    +24.46%
18:37:38 - Real-time Cboe. Currency in USD ( Disclaimer )
  • Volume: 6,410,665
  • Bid/Ask: 0.00 / 0.00
  • Day's Range: 149.06 - 178.68
Type:  Equity
Market:  United States
ISIN:  US6700024010 
CUSIP:  670002401
Novavax 176.56 +34.69 +24.46%

Overall Consensus

Buy Sell Neutral

Outperform

Analysts 12-Month Price Target

Average 260.60 (+47.60% Upside)

High | 305.00

Average | 260.60

Low | 172.00

Past 12 Months

12-Month Forecast

Data Based on a Poll of 6 Analysts

Technical Analysis

Summary:Strong Buy
Moving Averages:BuyBuy (7)Sell (5)
Technical Indicators:Strong BuyBuy (8)Sell (1)

Recent Sentiments

BearishBullish
Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

NVAX Comments

Write your thoughts about Novavax Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Inpatient PT
Inpatient PT Oct 29, 2021 15:23
Saved. See Saved Items.
This comment has already been saved in your Saved Items
What’s happening. Good news drop. R&D director sells. Why not sack him
Daniel Chang
Daniel Chang Oct 29, 2021 15:23
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Sure? is R&D director?
Roy Martinez
Roy Martinez Oct 21, 2021 6:52
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Is the Politico reported legal securities law violation investigation into Novavax for real or a diversion tactic.As private investors we will never know but everything we read and know for certain about Novavax points to a health Company ready to take off.The current lows of down to $120 should be a fantastic buying opportunity. If not then credibility in all stock news reports will be shattered and a potential trigger for a market plunge.
Kefah Mokbel
Kefah Mokbel Oct 20, 2021 15:29
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Purity is critical for vaccines
Daniel Chang
Daniel Chang Oct 20, 2021 13:02
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Novavax Reconfirms Confidence in Regulatory Filing Timelines and Manufacturing QualityOct 20, 2021
Aaron Murphy
Aaron Murphy Oct 20, 2021 11:16
Saved. See Saved Items.
This comment has already been saved in your Saved Items
strong sell now
Adnan Masood
Adnan Masood Sep 29, 2021 17:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why NVAX director sold around 26000 shares?
Daniel Chang
Daniel Chang Sep 29, 2021 17:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
to take profit. and buy in again at lower price.
Brett Chalmers
Brett Chalmers Sep 29, 2021 17:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Directors cant just buy and sell as they feel like. So they have pre agreed trading plans. Its just tradhy journos writing rubbish articles to sppok investors.. only motive i can see. They ate probdbly in bed with short sellers. What they usually dont make clear is that when they sell stock they also iften purchase options at the same time.
Zulkarnain Khoso Faiz
Zulkarnain Khoso Faiz Sep 27, 2021 20:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
buy its jackpot time next stop 290
Roy Martinez
Roy Martinez Sep 27, 2021 20:24
Saved. See Saved Items.
This comment has already been saved in your Saved Items
If the vaccination route is overtaken by a single pill it will have a negative impact for NVAX and MRNA Assuming the pill is not FDA approved can see by year end NVAX breaking through $300.
Thanish Thanu
Thanish Thanu Aug 24, 2021 14:46
Saved. See Saved Items.
This comment has already been saved in your Saved Items
“We need an urgent reversal from the majority of vaccines going to high income countries, to the majority going to low income countries,” said WHO Director-General Tedros Adhanom Ghebreyesus.
Zulkarnain Khoso Faiz
Zulkarnain Khoso Faiz Aug 13, 2021 17:54
Saved. See Saved Items.
This comment has already been saved in your Saved Items
this gonna big 300 next stop
Noel Tan
Noel Tan Aug 10, 2021 11:15
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Never lose faith in this stock. Gonna be the next big vax!
Thanish Thanu
Thanish Thanu Aug 09, 2021 16:00
Saved. See Saved Items.
This comment has already been saved in your Saved Items
☝🏻☝🏻☝🏻☝🏻☝🏻
George Tan
George Tan Aug 08, 2021 13:59
Saved. See Saved Items.
This comment has already been saved in your Saved Items
surprise ... down for financial and another down on Monday I guess
Ian Hendriks
Ian Hendriks Aug 08, 2021 13:59
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Why surprise ??
George Tan
George Tan Aug 08, 2021 13:59
Saved. See Saved Items.
This comment has already been saved in your Saved Items
surprise surprise... down for financials and another down on Monday I guess
Noel Tan
Noel Tan Aug 05, 2021 20:17
Saved. See Saved Items.
This comment has already been saved in your Saved Items
One of the best stocks to get.. Will easily rise to 300 with the EU deal.
Brett Chalmers
Brett Chalmers Aug 05, 2021 16:57
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Modernas current market capitalisation is 10x that of Novavax.. inderatand they got a head start but given the results and based on the deal with EU, suggests filing for regulatory approval is imminent. Post approval novavax have a vaccine that is at least as good and also have a stage 3 flu vaccine as good or better than anything on the market. So combo flu / covid boosters = advantage novavax at current valuations.
Thanish Thanu
Thanish Thanu Jul 20, 2021 15:05
Saved. See Saved Items.
This comment has already been saved in your Saved Items
250+?
abc bbc
abc bbc Jul 06, 2021 18:09
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Novavax unable to get approval from any country so far. Only trials that say 90% effective but no approval as production process not ironed out. Q1 approval application delayed to Q3 already. 2021 sales of vaccine in doubt.
Brett Chalmers
Brett Chalmers Jul 06, 2021 18:09
Saved. See Saved Items.
This comment has already been saved in your Saved Items
They’ve already signed purchase agreement for 270 odd mllion in developed countries and over a billion for low and middle income. So not sure sales will be an issue.
abc bbc
abc bbc Jul 06, 2021 18:09
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not denying that they have orders but question is one of delivery. Maybe 2022 will be when they can start but till regulatory approvals start coming later this year, they remain behind the curve of other vax providers.
Roy Hakin
Roy Hakin Jul 01, 2021 8:03
Saved. See Saved Items.
This comment has already been saved in your Saved Items
NEJM.ORG announce Novax is safe !!
Heejong Yoo
Heejong Yoo May 12, 2021 8:38
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Korea Drug and Food Safety official just before confirmed again they are now pre-reviewing the clinical trial data and will rapidly proceed the approval process as soon as SK Biosciense/NVAX submit their P3 approval documents regardless of the NVAX's filing plan in Q3 for FDA, MHRA and EMA.
Heejong Yoo
Heejong Yoo May 12, 2021 7:35
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Korean government said this morning (May 12th in Korea time) they have no change with the existing rollout and admin plans of NVAX vaccine in Korea as Korean FDA is now reviewing the NVAX's clinical trial data submitted by SK Bioscience in parallel with and/or independent of FDA, MHRA and EMA.SK Biosciense now keeps their validation (It might seem to have been completed as they said last month their validation vaccine could be used for commercial purpose.) or commercial operation going and plans to commercially rollout 30m doses of the NVAX vaccine this year and another 10m doses in the early of next year to start to provide them to Korean government from June or July of this year. Korea Ministry of Food and Drug Safety is likely to approve the NVAX jab firstly in the world in next month as Korea President, Mr. Moon announced Monday (May 10) Korea government seems to move up their jab inoculation plan which is to achieve the herd immunity by November. It seems Korea government knows something that the US P3 results would NOT be different from the UK P3 results. Let's see what will happen soon....
Brett Chalmers
Brett Chalmers May 12, 2021 7:35
Saved. See Saved Items.
This comment has already been saved in your Saved Items
So is there an expectation on when they will approve?
Aaron Murphy
Aaron Murphy May 03, 2021 18:19
Saved. See Saved Items.
This comment has already been saved in your Saved Items
dud
Brett Chalmers
Brett Chalmers May 03, 2021 18:19
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Not sure how you work that out. Highest efficacy of all the vaccines against the original strain. Their technology also delivered the first malaria vaccine over 75 percent efficacy in a recent trial and its late stafe flu vaccine is as good or better than anything currently on the market. The only duds are the morons currently panic selling on the eve of approvals and a supply agreement with the EU.
Yonka Dimitrova
Yonka Dimitrova Mar 25, 2021 17:51
Saved. See Saved Items.
This comment has already been saved in your Saved Items
the support is coming at 140
Brett Chalmers
Brett Chalmers Mar 23, 2021 19:45
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Cant understand the selloff with approvals pending. Makes no sense.
Roy Martinez
Roy Martinez Mar 23, 2021 19:45
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Guess the Company History with failed drug research does not help. However if they get FDA approval ( late April ?)they could soar to $400 plus.
Geoffrey Lee
Geoffrey Lee Mar 04, 2021 23:57
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Court case. Great!
Roy Martinez
Roy Martinez Mar 04, 2021 23:57
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Please clarify - what court case ?
Lena Payne
Lena Payne Feb 18, 2021 23:06
Saved. See Saved Items.
This comment has already been saved in your Saved Items
1.1billion vaccine deal for nvax announced this evening
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
Continue with Google
or
Sign up with Email